Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells

In pre-clinical studies, triple-negative breast cancer (TNBC) cells have demonstrated sensitivity to the multi-targeted kinase inhibitor dasatinib; however, clinical trials with single-agent dasatinib showed limited efficacy in unselected populations of breast cancer, including TNBC. To study potent...

Descripción completa

Detalles Bibliográficos
Autores principales: Gaule, Patricia, Mukherjee, Nupur, Corkery, Brendan, Eustace, Alex J., Gately, Kathy, Roche, Sandra, O’Connor, Robert, O’Byrne, Kenneth J., Walsh, Naomi, Duffy, Michael J., Crown, John, O’Donovan, Norma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520724/
https://www.ncbi.nlm.nih.gov/pubmed/30999598
http://dx.doi.org/10.3390/cancers11040548

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6520724/
https://www.ncbi.nlm.nih.gov/pubmed/30999598
http://dx.doi.org/10.3390/cancers11040548

Ejemplares similares